WEST PALM BEACH, FL 33401 – June 23rd, 2023 – Prostasis Receives Patent Approval From the USPTO for its “Nutra-Similar” Weight Loss and Brain Health .
Prostasis, a growth-stage developer of nutra-similar supplements, announced that the US Patent and Trademark Office (USPTO) has granted patents for its line of “nutra-similar” products designed to support metabolic and brain health using safe, natural ingredients.
The company, founded by former pharmaceutical executives, has conducted extensive research into developing these “nutra-similars,” which are over-the-counter nutraceutical supplements that exhibit similar benefits to prescribed medications without the adverse side effects.
The products, branded as NutraMeta™ for weight loss and NutraMind™ for brain health, are set to be available as daily capsules and a supplement bar starting in early 2025.
“Following rigorous research and development, we are excited to introduce these supplements as affordable options for individuals looking for support with weight management and cognitive health,” said Mark Brosso, Founder of Prostasis. “Our products contain natural ingredients that have been used safely by humans for centuries and researched extensively for their potential benefits in supporting overall health.”
Throughout 2024, Prostasis will finalize the formulation and packaging of both NutraMeta™ and NutraMind™.
For corporate or product inquiries, please contact info@prostasis.com.